911 results on '"Mullier, François"'
Search Results
2. Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology
3. Is lupus anticoagulant testing with dilute Russell’s viper venom clotting times reliable in the presence of inflammation?
4. The use of 1E12, a monoclonal anti-platelet factor 4 antibody, to improve the diagnosis of vaccine-induced immune thrombotic thrombocytopenia
5. Which Strategies Should We Use to Reduce Inappropriate Use of Laboratory Resources in the ICU: Guidelines are Urgently Needed!
6. Minimal requirements for ISO15189 validation and accreditation of three next generation sequencing procedures for SARS-CoV-2 surveillance in clinical setting
7. Laboratory Monitoring of Heparin Anticoagulation in Hemodialysis: Rationale and Strategies
8. Reassessment of dextran sulfate in anti-Xa assay for unfractionated heparin laboratory monitoring
9. Multicenter evaluation of light transmission platelet aggregation reagents: communication from the ISTH SSC Subcommittee on Platelet Physiology
10. Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US
11. Guidelines for the prescription of standard hematology and biochemistry clinical laboratory tests in the intensive care unit: A scoping review protocol.
12. The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
13. Multicentre evaluation of 5B9, a monoclonal anti‐PF4/heparin IgG mimicking human HIT antibodies, as an internal quality control in HIT functional assays: Communication from the ISTH SSC Subcommittee on Platelet Immunology
14. Laboratory evaluation of a new integrative assay to phenotype plasma fibrinolytic system
15. Heparin‐induced thrombocytopenia: Construction of a pretest diagnostic score derived from the analysis of a prospective multinational database, with internal validation
16. Diagnosis and management of heparin-induced thrombocytopenia
17. “Defining Heparin Resistance: Communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis”: comment from Gouin-Thibault et al.
18. Laboratory Monitoring of Heparin Anticoagulation in Hemodialysis: Rationale and Strategies
19. EVpedia: a community web portal for extracellular vesicles research
20. Assessment of the analytical performances and sample stability on ST Genesia system using the STG‐DrugScreen application
21. Management of Therapeutic-intensity Unfractionated Heparin: A Narrative Review on Critical Points
22. Reassessment of dextran sulfate in anti-Xa assay for UFH laboratory monitoring
23. P-022 Avantages don de double concentré de globules rouges
24. Clinical studies on platelet transfusion: Time to consider methodological issues related to platelet counting
25. Assessment of the individual determinants of two fibrinolysis assays, GFC and ECLT in platelet-depleted plasma and derived euglobulin fraction respectively
26. Corrigendum to “Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?” [Thromb. Res. 236 (2024) 236–239 TR_8963]
27. Position du GIHP sur les tests viscoélastiques : quelle place pour quelle indication en situation hémorragique ?
28. Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?
29. “Finding a common definition of heparin resistance in adult cardiac surgery: Communication from the ISTH SSC Subcommittee on Perioperative and Critical Care Thrombosis and Hemostasis”: comment from Mansour et al.
30. Serial fibrin monomer and D-dimer plasma levels measurements can capture thrombotic complications in critically ill COVID-19 patients: A prospective observational study.
31. Are Viscoelastometric Assays of Old Generation Ready for Disposal? Comment on Volod et al. Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. 2022, , 860.
32. Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab: Focus on platelet extracellular vesicles
33. Are Viscoelastometric Assays of Old Generation Ready for Disposal? Comment on Volod et al. Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. J. Clin. Med. 2022, 11, 860
34. Letter in response to Othman & Favaloro “Comparison of two ways of performing ristocetin-induced platelet agglutination (RIPA) mixing study for diagnosis of type 2B VWD”
35. D-dimer testing: A narrative review
36. Multi-center evaluation of light transmission platelet aggregation reagents: Communication from the ISTH SSC Subcommittee on Platelet Physiology
37. Are Viscoelastometric Assays of Old Generation Ready for Disposal? Comment on Volod et al. Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. 2022, , 860
38. Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia
39. Resistance towards ChadOx1 nCoV-19 in an 83 Years Old Woman Experiencing Vaccine Induced Thrombosis with Thrombocytopenia Syndrome
40. Assessment of DOAC in GEriatrics (Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients
41. D-dimer Testing in Pulmonary Embolism with a Focus on Potential Pitfalls: A Narrative Review
42. Variability among commercial batches of normal pooled plasma in lupus anticoagulant testing
43. Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controls
44. Microparticle bearing tissue factor: A link between promyelocytic cells and hypercoagulable state
45. SLC14A1 gene sequencing shows the JK*01W.06 allele in a JK1 patient with an anti-JK1
46. European guidelines on perioperative venous thromboembolism prophylaxis: Patients with preexisting coagulation disorders and after severe perioperative bleeding
47. Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study
48. Laboratory Testing for the Evaluation of Phenotypic Activated Protein C Resistance
49. Implementation of the new EUR IVD regulation and relation with ISO15189 accreditation: Guidance is urgently required for haemostasis testing
50. D-dimer: old dogmas, new (COVID-19) tricks
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.